Healthcare Firm Targets Alzheimer's With Technology Breakthrough
Source: Streetwise Reports  (9/5/25)
Healthcare company Algernon Health (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) rebrands and unveils plan to open brain-specific PET scanning clinics in North America to meet rising demand for Alzheimer's diagnostics. Read more to learn how this shift positions the company at the center of a growing medical need. More >

Seeking Formulation of New Drug, Biopharma Co. Signs LOI
Source: Dr. Douglas Loe  (9/5/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) is seeking a novel formulation or drug delivery modalities that could modify the pharmacokinetics of its anti-cancer drug kt3283 to be more tumor targeted, noted a Leede Financial Inc. report. More >

New Remission Data on MG Patients Compelling
Source: Mitchell Kapoor  (9/5/25)
Kyverna Therapeutics Inc.'s (KYTX:NASDAQ) KYV-101 cell therapy drives a 15-month and longer remission in three patients treated on a compassionate use basis, noted an H.C. Wainwright & Co. report. More >

Biopharma Firm Accelerates AI-Driven Cancer Drug Discovery in Canada
Source: Streetwise Reports  (9/3/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) secured fresh funding, advanced preclinical PARP and ATR programs, and leveraged exclusive AI platforms to target DNA-repair pathways. Read more for insight into its expanding role in precision oncology. More >

Cell Therapy Firm Kyverna Advances U.S. Phase 3 MG Trial
Source: Streetwise Reports  (9/3/25)
Kyverna Therapeutics Inc. (KYTX:NASDAQ) unveiled the design of its U.S. registrational Phase 3 trial for KYV-101 in myasthenia gravis during a Key Opinion Leader event, following ≥ 15-month remission data in Germany. Read more to see what sets this trial apart. More >

Healthcare AI Company Rebrands as Rocket Doctor AI to Pursue Growing Market Opportunities
Source: Streetwise Reports  (8/27/25)
Treatment.com AI Inc. has rebranded and reincorporated as Rocket Doctor AI (AIDR:CSE; TREIF:OTC; 939:FRA) to reflect the integration of its proprietary AI-driven Global Library of Medicine (GLM) with the recently acquired Rocket Doctor Inc. Read why one analyst calls part of the company's offerings "Shopify for physicians." More >

AI Healthcare Stock Showing Signs of a Base Breakout
Source: John Newell  (8/25/25)
John Newell of John Newell & Associates explains why he thinks Rocket Doctor AI (AIDR:CSE; TREIF:OTC; 939:FRA) is a Speculative Buy. More >

Cleantech Co. Advances Innovative Systems for Data Centers
Source: Streetwise Reports  (8/19/25)
Environmental and cleantech company BioLargo Inc. (BLGO:OTCQX) announces its financial results, including a huge increase in revenue in its engineering segment due to contracts to provide control compliance services. More >

Co.'s Graphene Used in New Screening Test for Lung Cancer
Source: Streetwise Reports  (8/18/25)
HydroGraph Clean Power Inc.'s (HG:CSE; HGRAF:OTCQB; M98:FSE) patented, high-purity material has applications in healthcare, as in this case, but also in numerous other industries. Read on to learn why some experts say this company could be a future 100-bagger. More >

AI Biotech Company Plans Saudi Venture to Develop Cancer Drug
Source: Streetwise Reports  (8/14/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) has signed a Letter of Intent with NanoPalm to co-develop AI-discovered cancer treatments starting with kt-3283. Read how the experimental drug targets hard-to-treat tumors and may signal a broader pipeline to come More >

Medical Co.'s New Joint Venture Could Expand Co.'s Footprint
Source: Dr. Douglas Loe  (8/13/25)
Leede Financial Inc. analyst Dr. Douglas Loe gave this company a Buy rating. More >

Pharmaceutical Company Discovers Breakthrough Heart Treatment in Canada
Source: Jason Wittes  (8/11/25)
Top-line results from Cardiol Therapeutics' (CRDL:TSX; CRDL:NASDAQ) ARCHER study for Acute Myocarditis are quite promising, writes Roth Capital Partners Analyst Jason Wittes in an updated research note. More >

Biotech Announces Topline Results From Cardiovascular Drug Trial
Source: Brandon Folkes  (8/11/25)
Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) Analyst Brandon Folkes reviews Cardiol Therapeutics Inc. after it announced the topline results from its Phase II ARCHER trial of CardiolRx in acute myocarditis. More >

Canadian Pharmaceutical Company Discovers Breakthrough Cardiovascular Treatment
Source: Streetwise Reports  (8/11/25)
Clinical-stage life sciences company Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) announces topline results from its Phase II clinical study involving patients with acute myocarditis. Read why analysts like this pharmaceutical stock. More >

Canadian Pharma Finds Promising Cardiovascular Breakthrough
Source: Douglas Loe  (8/8/25)
Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) reports headline Phase II data from its 109-patient acute myocarditis study, known as the ARCHER trial. Read to see how one analyst rates the stock. More >

Cleantech/Life Sciences Co. Advances Products in Q2/25
Source: Richard Ryan  (8/4/25)
BioLargo Inc. (BLGO:OTCQX) enters into several agreements, forms partnerships and receives third party product validation, noted an Oak Ridge Financial report. More >

Clean Tech Firm Making Important PFAS Breakthrough
Source: Streetwise Reports  (7/29/25)
Clean technology company BioLargo Inc. (BLGO:OTCQX) president and chief executive office shares a mid-year update on the company's achievements so far this year, along with insights into its future prospects through a letter to shareholders. More >

Cancer Drug Developer Finds Potent Hits With AI in British Columbia
Source: Streetwise Reports  (7/25/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) taps machine learning to zero in on novel cancer therapies. Read more about the AI engine driving this high-stakes discovery. More >

Pancreas Cancer Becoming Top Focus for Biotech Co.?
  (7/22/25)
Oncolytics Biotech Inc. (ONCY:NASDAQ; ONC:TSX) published survival data for the use of its immunotherapy pelareorep in pancreatic cancer, and these support the view that this indication should be primary, noted a Leede Financial Inc. report. More >

Biotech Firm Clears Major U.S. Trading Hurdle
Source: Streetwise Reports  (7/18/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) just gained DTC eligibility, opening the door for faster U.S. trades and broader investor access. With AI-driven cancer drugs in development, analysts are taking notice. Read more to find out why. More >

Portable Rapid Testing Kit Drives Development of 'Forever Chemical' Solution
Source: Streetwise Reports  (7/15/25)
BioLargo Inc. (BLGO:OTCQX) announced it has initiated "alpha testing" of a PFAS-detecting portable water test kit. Find out why one analyst says the stock is a Buy. More >

Biotech Partnership to Revolutionize Diabetes Treatment
Source: Streetwise Reports  (7/15/25)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) announces a collaborative research agreement with Eledon Pharmaceuticals Inc. to assess Eledon's immunosuppressive drug in Sernova's ongoing trials of its cell pouch biohybrid organ for patients with Type 1 diabetes (T1D). More >

Biotech Enters Agreement with Co. Behind Tegoprubart
Source: Dr. Joseph Pantginis  (7/14/25)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) likely will use this new monoclonal antibody as an immunosuppressant in its Phase 1/2 trial's Cohort C instead of previously used tacrolimus, noted an H.C. Wainwright & Co. report. More >

AI Healthtech Firm Partners with EngageWell and CVS Health Foundation on NYC Senior Care Initiative
Source: Streetwise Reports  (7/14/25)
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) launches virtual screening for older adults in NYC, backed by US$1M from CVS Health Foundation, as it scales AI tools and patient reach. Read more about how this initiative is helping expand access to care and driving growth in virtual health innovation. More >

Biopharma Firm Assembles Elite AI Cancer Team
Source: Streetwise Reports  (7/11/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) strengthens its AI-driven cancer program with a world-class advisory board and breakthrough drug discovery platforms. Read more about how Rakovina's expert-backed strategy and proprietary platforms support next-gen oncology drug development and potential licensing deals. More >